Literature DB >> 7519874

Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I.

D H Gutmann1, J L Cole, W J Stone, B A Ponder, F S Collins.   

Abstract

The neurofibromatosis type I gene encodes a protein, neurofibromin, which may function as a tumor suppressor gene product. Recent studies have demonstrated loss of neurofibromin in tumors from NF1 and non-NF1 patients, including neurofibrosarcomas, neuroblastomas and malignant melanomas. Since neurofibromin is expressed in the adrenal gland, six pheochromocytomas and one adrenal cortical tumor were examined for neurofibromin expression. In all seven tumors, no neurofibromin could be detected. Furthermore, loss of heterozygosity (LOH) analysis demonstrated that in one of the pheochromocytomas, reduction to homozygosity was observed for both 17p and 17q markers while the adrenal cortical tumor demonstrated LOH for only 17q markers. The frequent LOH surrounding the NF1 locus and lack of neurofibromin expression in these tumors suggest that NF1 gene mutations may contribute to the development of adrenal gland neoplasms in patients with NF1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519874     DOI: 10.1002/gcc.2870100109

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells.

Authors:  D Muir; D Neubauer; I T Lim; A T Yachnis; M R Wallace
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  Immunohistochemical NF1 analysis does not predict NF1 gene mutation status in pheochromocytoma.

Authors:  Adam Stenman; Fredrika Svahn; Jenny Welander; Boel Gustavson; Peter Söderkvist; Oliver Gimm; C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

Review 3.  [New aspects of tumor pathology of the adrenal glands].

Authors:  W Saeger
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 4.  Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.

Authors:  Giuseppe Opocher; Pierantonio Conton; Francesca Schiavi; Beatrice Macino; Franco Mantero
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 5.  Signal transduction pathways and their relevance in human astrocytomas.

Authors:  M M Feldkamp; N Lau; A Guha
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

6.  Characterization of Pheochromocytomas in a Mouse Strain with a Targeted Disruptive Mutation of the Neurofibromatosis Gene Nf1.

Authors:  Arthur S. Tischler; T. Shane Shih; Bart O. Williams; Tyler Jacks
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

Review 7.  Advances in the treatment of neurofibromatosis-associated tumours.

Authors:  Andrew L Lin; David H Gutmann
Journal:  Nat Rev Clin Oncol       Date:  2013-08-13       Impact factor: 66.675

8.  Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient.

Authors:  Karolina Kobus; Daniela Hartl; Claus Eric Ott; Monika Osswald; Angela Huebner; Maja von der Hagen; Denise Emmerich; Jirko Kühnisch; Hans Morreau; Frederik J Hes; Victor F Mautner; Anja Harder; Sigrid Tinschert; Stefan Mundlos; Mateusz Kolanczyk
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis.

Authors:  Ravi Kumar Menon; Francesco Ferrau; Tom R Kurzawinski; Gill Rumsby; Alexander Freeman; Zahir Amin; Márta Korbonits; Teng-Teng L L Chung
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-11-01

10.  Clonality Studies in the Analysis of Adrenal Medullary Proliferations: Application Principles and Limitations.

Authors:  Salvador J. Diaz-Cano
Journal:  Endocr Pathol       Date:  1998       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.